
Raluca Pais

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1470927/publications.pdf Version: 2024-02-01



PALLICA DAIS

#	Article	IF	CITATIONS
1	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology, 2022, 76, 456-468.	3.6	22
2	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Biomedicines, 2022, 10, 699.	1.4	7
3	Natural History of NAFLD. Journal of Clinical Medicine, 2021, 10, 1161.	1.0	23
4	Editorial: statin use in patients with NAFLD—safety concerns, decreased awareness or both?. Alimentary Pharmacology and Therapeutics, 2021, 54, 1499-1500.	1.9	1
5	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 72, 828-838.	1.8	52
6	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. European Journal of Gastroenterology and Hepatology, 2020, 32, 998-1007.	0.8	8
7	Editorial: it is not a wideâ€open field for incretins ―collateral benefits favour the use of metformin in advanced nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 611-612.	1.9	0
8	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 393-402.	0.8	12
9	LCR1 and LCR2, two multiâ€analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 308-320.	1.9	15
10	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. European Journal of Gastroenterology and Hepatology, 2018, 30, 569-577.	0.8	15
11	Longâ€ŧerm prognostic value of the FibroTest in patients with nonâ€alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1117-1127.	1.9	28
12	Temporal trends, clinical patterns and outcomes of <scp>NAFLD</scp> â€related <scp>HCC</scp> in patients undergoing liver resection over a 20â€year period. Alimentary Pharmacology and Therapeutics, 2017, 46, 856-863.	1.9	91
13	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini�― Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 432-439.	0.7	10